Lapatinib (INN), used in the form of lapatinib ditosylate (USAN) (trade names Tykerb and Tyverb marketed by Novartis) is an orally active drug for breast...
18 KB (1,504 words) - 01:24, 12 October 2024
Quinazoline (section Lapatinib)
drug lapatinib was approved by the U.S. FDA to treat advanced-stage or metastatic breast cancer in combination with Roche's capecitabine. Lapatinib eliminates...
14 KB (1,247 words) - 23:51, 10 December 2024
8 months (30.9 months vs. 25.1 months) compared to the combination of lapatinib and capecitabine. Based on that trial, the U.S. Food and Drug Administration...
29 KB (2,696 words) - 14:16, 27 July 2024
Lantidra Lantrisul Lantus (Sanofi-Aventis) lapaquistat acetate (USAN) lapatinib ditosylate (USAN) lapirium chloride (INN) laprafylline (INN) lapuleucel-T...
4 KB (282 words) - 04:39, 24 November 2024
while attempting to determine the toxicity and effectiveness of the drug. Lapatinib, FDA-approved for treatment in conjunction with chemotherapy or hormone...
10 KB (1,179 words) - 18:31, 8 August 2024
this setting. Sorafenib (Nexavar) Sunitinib (Sutent) Dasatinib (Sprycel) Lapatinib (Tykerb) Nilotinib (Tasigna) Bosutinib (Bosulif) Ponatinib (Iclusig) Asciminib...
20 KB (2,234 words) - 01:21, 22 July 2024
to develop new therapeutic strategies. HER2 kinase inhibitors, such as lapatinib, have also demonstrated clinical efficacy in HER2 overexpressing breast...
18 KB (2,105 words) - 01:40, 20 August 2024
inhibitors: Agerafenib Altiratinib Axitinib Cabozantinib Cediranib Fruquintinib Lapatinib Lenvatinib Motesanib Nintedanib Pazopanib Pegaptanib Rebastinib Regorafenib...
73 KB (6,489 words) - 08:56, 21 December 2024
1) SPOCK2 (Testican 2) SPOCK3 (Testican 3) Testican-1 plays a role in lapatinib resistance, which is a drug used to treat HER2-positive gastric cancer...
2 KB (239 words) - 07:09, 17 November 2023
antibody margetuximab can also prolong survival, as can HER2 inhibitors lapatinib, neratinib, or tucatinib. Certain therapies are targeted at those whose...
140 KB (15,850 words) - 09:01, 2 January 2025
inhibitors: Agerafenib Altiratinib Axitinib Cabozantinib Cediranib Fruquintinib Lapatinib Lenvatinib Motesanib Nintedanib Pazopanib Pegaptanib Rebastinib Regorafenib...
149 KB (15,719 words) - 16:46, 9 December 2024
inhibitors: Agerafenib Altiratinib Axitinib Cabozantinib Cediranib Fruquintinib Lapatinib Lenvatinib Motesanib Nintedanib Pazopanib Pegaptanib Rebastinib Regorafenib...
64 KB (7,432 words) - 08:21, 28 October 2024
inhibitors: Agerafenib Altiratinib Axitinib Cabozantinib Cediranib Fruquintinib Lapatinib Lenvatinib Motesanib Nintedanib Pazopanib Pegaptanib Rebastinib Regorafenib...
11 KB (666 words) - 00:54, 27 December 2024
Clinical trials are in progress for other drugs such as everolimus, lapatinib and mifepristone. Common aspirin has been studied as a low-risk therapeutic...
59 KB (6,712 words) - 12:11, 4 December 2024
vulnerability to oxytosis/ferroptosis via a combination of siramesine and lapatinib. These cells also exhibited an autophagic cycle independent of ferroptotic...
64 KB (6,608 words) - 05:50, 2 January 2025
inhibitors: Agerafenib Altiratinib Axitinib Cabozantinib Cediranib Fruquintinib Lapatinib Lenvatinib Motesanib Nintedanib Pazopanib Pegaptanib Rebastinib Regorafenib...
10 KB (1,131 words) - 19:14, 31 March 2024
inhibitors: Agerafenib Altiratinib Axitinib Cabozantinib Cediranib Fruquintinib Lapatinib Lenvatinib Motesanib Nintedanib Pazopanib Pegaptanib Rebastinib Regorafenib...
25 KB (1,825 words) - 05:46, 16 December 2024
Temsirolimus L01EG02 Everolimus L01EG03 Ridaforolimus L01EG04 Sirolimus L01EH01 Lapatinib L01EH02 Neratinib L01EH03 Tucatinib L01EJ01 Ruxolitinib L01EJ02 Fedratinib...
13 KB (935 words) - 04:36, 23 December 2024
inhibitors: Agerafenib Altiratinib Axitinib Cabozantinib Cediranib Fruquintinib Lapatinib Lenvatinib Motesanib Nintedanib Pazopanib Pegaptanib Rebastinib Regorafenib...
16 KB (868 words) - 08:35, 27 December 2024
proliferation and migration is diminished. Gefitinib, erlotinib, brigatinib and lapatinib (mixed EGFR and ERBB2 inhibitor) are examples of small molecule kinase...
60 KB (6,879 words) - 14:26, 16 July 2024
inhibitors: Agerafenib Altiratinib Axitinib Cabozantinib Cediranib Fruquintinib Lapatinib Lenvatinib Motesanib Nintedanib Pazopanib Pegaptanib Rebastinib Regorafenib...
26 KB (2,420 words) - 02:40, 26 September 2024
inhibitors: Agerafenib Altiratinib Axitinib Cabozantinib Cediranib Fruquintinib Lapatinib Lenvatinib Motesanib Nintedanib Pazopanib Pegaptanib Rebastinib Regorafenib...
46 KB (5,344 words) - 15:43, 27 November 2024
inhibitors: Agerafenib Altiratinib Axitinib Cabozantinib Cediranib Fruquintinib Lapatinib Lenvatinib Motesanib Nintedanib Pazopanib Pegaptanib Rebastinib Regorafenib...
18 KB (1,573 words) - 05:19, 15 October 2024
approved anti-HER2 therapeutics are also tyrosine kinase inhibitors (Lapatinib, Neratinib, and Tucatinib) and antibody-drug conjugates (ado-trastuzumab...
43 KB (4,657 words) - 07:27, 28 November 2024
trastuzumab-containing combination therapies (with chemotherapy, hormone blockers, or lapatinib) for the treatment of metastatic breast cancer.[clarification needed]...
70 KB (6,131 words) - 08:28, 27 December 2024
inhibitors: Agerafenib Altiratinib Axitinib Cabozantinib Cediranib Fruquintinib Lapatinib Lenvatinib Motesanib Nintedanib Pazopanib Pegaptanib Rebastinib Regorafenib...
93 KB (8,733 words) - 03:33, 16 December 2024
inhibitors: Agerafenib Altiratinib Axitinib Cabozantinib Cediranib Fruquintinib Lapatinib Lenvatinib Motesanib Nintedanib Pazopanib Pegaptanib Rebastinib Regorafenib...
31 KB (3,421 words) - 06:52, 2 November 2024
inhibitors: Agerafenib Altiratinib Axitinib Cabozantinib Cediranib Fruquintinib Lapatinib Lenvatinib Motesanib Nintedanib Pazopanib Pegaptanib Rebastinib Regorafenib...
5 KB (412 words) - 23:17, 19 June 2023
inhibitors: Agerafenib Altiratinib Axitinib Cabozantinib Cediranib Fruquintinib Lapatinib Lenvatinib Motesanib Nintedanib Pazopanib Pegaptanib Rebastinib Regorafenib...
7 KB (492 words) - 08:38, 3 October 2024
inhibitors: Agerafenib Altiratinib Axitinib Cabozantinib Cediranib Fruquintinib Lapatinib Lenvatinib Motesanib Nintedanib Pazopanib Pegaptanib Rebastinib Regorafenib...
6 KB (596 words) - 06:45, 1 January 2025